clodronic acid has been researched along with Bone Loss, Perimenopausal in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (27.27) | 18.2507 |
| 2000's | 17 (51.52) | 29.6817 |
| 2010's | 7 (21.21) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adami, S; Dartizio, C; Fracassi, E; Gatti, D; Idolazzi, L; Ionescu, C; Kunnathully, V; Rossini, M; Troplini, S; Viapiana, O | 1 |
| Baraldi, E; Cremonesi, G; Frediani, B | 1 |
| Jalava, T; Johansson, H; Kanis, JA; Kayan, K; McCloskey, EV; Oden, A; Pande, K; Vasireddy, S | 1 |
| Johansson, H; Kanis, JA; Kayan, K; McCloskey, EV; Oden, A; Orgee, J; Pande, K; Vasireddy, S | 1 |
| Kessenich, C | 1 |
| Calcagnile, F; Muratore, M; Quarta, E; Quarta, L | 1 |
| Alhava, E; Härmä, K; Honkanen, R; Jurvelin, J; Kiviniemi, V; Komulainen, M; Kröger, H; Saarikoski, S; Tuppurainen, M | 1 |
| Frediani, B | 1 |
| Calcagnile, F; Grimaldi, A; Muratore, M; Quarta, E; Quarta, L | 1 |
| Baraldi, E; Cremonesi, G; Leuratti, C; Mariotti, F; Radicioni, M | 1 |
| Ala-Kaila, K; Aranko, SM; Blåfield, H; Koivunoro, K; Kormano, M; Laitinen, K; Mäkinen, L; Patronen, A; Perttilä, J; Puolijoki, H; Pylkkänen, L; Rekiaro, M; Sairanen, S; Salmi, J; Seppänen, J; Väisänen, K; Välimäki, MJ; Vesterinen, K | 1 |
| Fietta, P; Lodigiani, L; Manganelli, P | 1 |
| Calcagnile, F; Carlo Isaia, G; Cosentino, L; D'Amelio, P; Muratore, M; Quarta, E; Tamone, C; Tinelli, F | 1 |
| Adami, S; Crepaldi, G; Filipponi, P; Sartori, L | 1 |
| Adams, J; Aropuu, S; Beneton, M; Davies, M; Francis, RM; Jalava, T; Kanis, JA; Kayan, K; Kenraali, J; McCloskey, E; Pylkkänen, L; Robinson, J; Selby, P | 1 |
| Alessi, MA; Barbagallo, M; Belvedere, M; Bevilacqua, M; Costanza, G; Dominguez, LJ; Ferlisi, A; Galioto, A; Putignano, E | 1 |
| Langdahl, B; Mosekilde, L; Vestergaard, P | 1 |
| Alagöl, F; Bayraktaroglu, T; Boztepe, H; Tanakol, R; Yarman, S | 1 |
| Alva, D; Cesareo, R; Contini, S; De Rosa, B; Iozzino, M; Lauria, A; Mallardo, L; Napolitano, C; Orsini, A; Reda, G | 1 |
| Boldrini, S; Cini, L; Cristallini, S; Fedeli, L; Filipponi, P; Massoni, C; Palumbo, R; Pedetti, M | 1 |
| Hanhijärvi, H; Hyvönen, PM; Karhi, T; Kosma, VM; Liimola-Luoma, L | 1 |
| Crepaldi, G; D'Angelo, A; Dalle Carbonare, L; Giannini, S; Passeri, G; Sartori, L | 1 |
| Beneton, MN; Kanis, JA; McCloskey, EV | 1 |
| Licata, AA | 1 |
| Arnala, I; Heikkinen, JE; Laitinen, K; Selander, KS; Väänänen, HK | 1 |
| Gennari, C; Reginster, JY | 1 |
| Adami, S; Braga, V; Gatti, D; Gerardi, D; Rossini, M; Zamberlan, N | 1 |
| Cheng, WC; Chieng, PU; Hsu, SH; Tsai, KS; Yang, RS | 1 |
| del Puente, A; Ferrara, G; Itto, E; Oriente, P; Scognamiglio, A | 1 |
| Borean, A; De Prà, M; Farina, G; Nalin, P; Rizzotti, P | 1 |
| Watts, NB | 1 |
| Fini, M; Gnudi, S; Lisi, L; Malavolta, N | 1 |
| Biberoğlu, K; Noyan, V; Tiraş, MB; Yildiz, A | 1 |
9 review(s) available for clodronic acid and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Effect of clodronate treatment on risk of fracture: a systematic review and meta-analysis.
Topics: Bone Density Conservation Agents; Clodronic Acid; Female; Fracture Healing; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Probability; Prospective Studies; Randomized Controlled Trials as Topic | 2014 |
Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonates.
Topics: Clodronic Acid; Diphosphonates; Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal | 2011 |
Injectable bisphosphonates in the treatment of postmenopausal osteoporosis.
Topics: Anti-Inflammatory Agents; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Zoledronic Acid | 2003 |
Fracture prevention in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Hormone Replacement Therapy; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Pamidronate; Parathyroid Hormone; Risedronic Acid; Selective Estrogen Receptor Modulators; Vitamin D | 2006 |
Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes; Vitamin D | 2007 |
Clodronate and osteoporosis.
Topics: Administration, Oral; Aged; Bone Density; Clodronic Acid; Female; Humans; Infusions, Intravenous; Long-Term Care; Osteoporosis, Postmenopausal; Treatment Outcome | 1996 |
Bisphosphonate therapy.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoclasts; Osteoporosis; Osteoporosis, Postmenopausal; Pamidronate; Risedronic Acid | 1997 |
Bisphosphonates and osteoporosis treatment in Italy.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Italy; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Safety | 1998 |
Treatment of osteoporosis with bisphosphonates.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Risedronic Acid | 2001 |
19 trial(s) available for clodronic acid and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis.
Topics: Adaptor Proteins, Signal Transducing; Aged; Bone Density Conservation Agents; Bone Morphogenetic Proteins; Clodronic Acid; Diphosphonates; Female; Genetic Markers; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; Middle Aged; Osteoporosis, Postmenopausal; Zoledronic Acid | 2014 |
Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Algorithms; Bone Density; Bone Density Conservation Agents; Clodronic Acid; Double-Blind Method; Female; Fractures, Bone; Hip Joint; Humans; Osteoporosis, Postmenopausal; Probability; Risk Assessment; Risk Factors; Treatment Outcome; United Kingdom | 2009 |
Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate.
Topics: Accidental Falls; Aged; Aged, 80 and over; Algorithms; Bone Density; Bone Density Conservation Agents; Clodronic Acid; Epidemiologic Methods; Female; Femur Neck; Humans; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Prognosis; Treatment Outcome | 2009 |
"Twice-a-month" clodronate 200 mg IM: a new dosing regimen and improved therapy adherence in the treatment of postmenopausal osteoporosis.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Clodronic Acid; Drug Administration Schedule; Female; Femur; Humans; Lumbar Vertebrae; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Pain | 2010 |
Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up.
Topics: Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Clodronic Acid; Drug Therapy, Combination; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Femur; Finland; Follow-Up Studies; Humans; Lumbar Vertebrae; Middle Aged; Norethindrone; Norethindrone Acetate; Osteoporosis, Postmenopausal; Postmenopause; Prospective Studies | 2010 |
Effects of two administration schemes of intramuscular clodronic acid on bone mineral density: a randomized, open-label, parallel-group study.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Clodronic Acid; Drug Administration Schedule; Female; Humans; Injections, Intramuscular; Middle Aged; Osteoporosis, Postmenopausal | 2011 |
Pharmacokinetic and tolerability of i.m. disodium clodronate 200 mg/lidocaine 1%, given twice monthly, in comparison with i.m. disodium clodronate 100 mg/lidocaine 1%, given weekly, in healthy postmenopausal female patients.
Topics: Bone Density Conservation Agents; Clodronic Acid; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Injections, Intramuscular; Lidocaine; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Therapeutic Equivalency | 2013 |
Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
Topics: Absorptiometry, Photon; Bone Density; Bone Diseases, Metabolic; Clodronic Acid; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Hip Joint; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Spinal Diseases | 2002 |
Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women.
Topics: Absorptiometry, Photon; Aged; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Cholecalciferol; Clodronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2003 |
Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
Topics: Aged; Alkaline Phosphatase; Antimetabolites; Bone Density; Clodronic Acid; Collagen; Collagen Type I; Double-Blind Method; Female; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Peptides; Prospective Studies; Risk Factors; Spinal Fractures | 2004 |
Intermittent intramuscular clodronate therapy: a valuable option for older osteoporotic women.
Topics: Aged; Back Pain; Bone Density; Bone Density Conservation Agents; Calcium; Clodronic Acid; Drug Administration Schedule; Drug Therapy, Combination; Female; Femur; Humans; Injections, Intramuscular; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Pain Measurement; Treatment Outcome; Vitamin D | 2005 |
Clodronic acid in the treatment of postmenopausal osteoporosis.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Calcium; Clodronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Vitamin D; Vitamins | 2007 |
Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy.
Topics: Absorptiometry, Photon; Administration, Cutaneous; Adult; Analysis of Variance; Biomarkers; Bone Density; Bone Development; Clodronic Acid; Estradiol; Estrogen Replacement Therapy; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lumbar Vertebrae; Medroxyprogesterone; Middle Aged; Osteoporosis, Postmenopausal; Skin Absorption | 1995 |
Continuous and cyclical clodronate therapies and bone density in postmenopausal bone loss.
Topics: Absorptiometry, Photon; Aged; Bone Density; Bone Remodeling; Calcium; Clodronic Acid; Drug Administration Schedule; Female; Femur; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Time Factors | 1996 |
Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss.
Topics: Absorptiometry, Photon; Bone Density; Calcitriol; Calcium; Clodronic Acid; Collagen; Collagen Type I; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Etidronic Acid; Female; Femur Neck; Follow-Up Studies; Humans; Hydroxyproline; Injections, Intravenous; Longitudinal Studies; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Peptide Fragments; Peptides; Procollagen; Prospective Studies | 1997 |
Intramuscular clodronate therapy in postmenopausal osteoporosis.
Topics: Aged; Bone Density; Clodronic Acid; Female; Humans; Injections, Intramuscular; Middle Aged; Osteoporosis, Postmenopausal; Pain; Patient Compliance; Time Factors | 1999 |
The effectiveness of cyclic and continuous oral clodronate therapy on bone density and markers in osteopenic postmenopausal women.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Biomarkers; Bone and Bones; Bone Density; Bone Resorption; Clodronic Acid; Collagen; Collagen Type I; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Femur Neck; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Peptide Fragments; Peptides; Procollagen; Treatment Outcome | 1999 |
Intramuscular clodronate in nonresponders to oral alendronate therapy for osteoporosis.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Analgesics, Non-Narcotic; Bone Density; Case-Control Studies; Clodronic Acid; Female; Femur Neck; Humans; Injections, Intramuscular; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome | 2000 |
Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate.
Topics: Adult; Alkaline Phosphatase; Bone Density; Calcitonin; Calcium; Clodronic Acid; Drug Therapy, Combination; Estrogen Replacement Therapy; Female; Femur; Humans; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Phosphorus; Treatment Outcome | 2000 |
5 other study(ies) available for clodronic acid and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Postmenopausal osteoporosis. The role of intravenous bisphosphonates.
Topics: Bone Density Conservation Agents; Clodronic Acid; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; United States | 2008 |
Clodronate induced uveitis.
Topics: Aged; Antimetabolites; Clodronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Uveitis, Anterior | 2003 |
The influence of dichloromethylene bisphosphonate on the healing of a long bone fracture, composition of bone mineral and histology of bone in the rat.
Topics: Animals; Body Weight; Bone Density; Calcium; Clodronic Acid; Disease Models, Animal; Dose-Response Relationship, Drug; Drinking; Female; Femoral Fractures; Femur; Fluorides; Fracture Healing; Humans; Injections, Subcutaneous; Magnesium; Osteocalcin; Osteoporosis, Postmenopausal; Phosphorus; Rats; Rats, Sprague-Dawley | 1994 |
Levels of C-telopeptide fragments of collagen type I enable the monitoring and early adjustment of clodronate therapy in patients with postmenopausal osteoporosis.
Topics: Aged; Analgesics, Non-Narcotic; Clodronic Acid; Collagen; Drug Monitoring; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Peptide Fragments | 2000 |
Effect of intramuscular clodronate on bone mass and metabolism in osteoporotic women.
Topics: Aged; Analgesics, Non-Narcotic; Bone Density; Calcium; Clodronic Acid; Female; Femur Neck; Follow-Up Studies; Humans; Hydroxyproline; Injections, Intramuscular; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Phosphates | 2001 |